Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk has a lot riding on new diabetes therapy Ozempic, and says the once-weekly drug has made good headway in the US since its launch in February. Widely considered a blockbuster-in-waiting, Ozempic (semaglutide) had sales of 264m krone ($41m) in,_chasing_lillys_trulicity_1248087